PROSTIN E2- dinoprostone suppository
Pharmacia and Upjohn Company LLC

Prostin E2®
dinoprostone vaginal
suppository

DESCRIPTION
PROSTIN E2 Vaginal Suppository, an oxytocic, contains dinoprostone as the naturally occurring prostaglandin E2 (PGE2).

Its chemical name is (5Z,11α,13E,15S)-11,15-Dihydroxy-9-oxo-prosta-5,13-dien-1-oic acid and the structural formula is represented below:

```
O

```

The molecular formula is C_{20}H_{32}O_{5}. The molecular weight of dinoprostone is 352.5. Dinoprostone occurs as a white crystalline powder. It has a melting point within the range of 64° to 71°C. Dinoprostone is soluble in ethanol and in 25% ethanol in water. It is soluble in water to the extent of 130 mg/100 mL.

Each suppository contains 20 mg of dinoprostone in a mixture of glycerides of fatty acids.

CLINICAL PHARMACOLOGY
PROSTIN E2 Vaginal Suppository administered intravaginally stimulates the myometrium of the gravid uterus to contract in a manner that is similar to the contractions seen in the term uterus during labor. Whether or not this action results from a direct effect of dinoprostone on the myometrium has not been determined with certainty at this time. Nonetheless, the myometrial contractions induced by the vaginal administration of dinoprostone are sufficient to produce evacuation of the products of conception from the uterus in the majority of cases.

Dinoprostone is also capable of stimulating the smooth muscle of the gastrointestinal tract of man. This activity may be responsible for the vomiting and/or diarrhea that is not uncommon when dinoprostone is used to terminate pregnancy.

In laboratory animals, and also in man, large doses of dinoprostone can lower blood pressure, probably as a consequence of its effect on the smooth muscle of the vascular system. With the doses of dinoprostone used for terminating pregnancy this effect has not been clinically significant. In laboratory animals, and also in man, dinoprostone can elevate body temperature. With the clinical doses of dinoprostone used for the termination of pregnancy some patients do exhibit temperature increases.

INDICATIONS AND USAGE
1. PROSTIN E2 Vaginal Suppository is indicated for the termination of pregnancy from the 12th
through the 20th gestational week as calculated from the first day of the last normal menstrual period.

2. PROSTIN E2 is also indicated for evacuation of the uterine contents in the management of missed abortion or intrauterine fetal death up to 28 weeks of gestational age as calculated from the first day of the last normal menstrual period.

3. PROSTIN E2 is indicated in the management of nonmetastatic gestational trophoblastic disease (benign hydatidiform mole).

CONTRAINDICATIONS

1. Hypersensitivity to dinoprostone [see WARNINGS and ADVERSE REACTIONS]
2. Acute pelvic inflammatory disease
3. Patients with active cardiac, pulmonary, renal, or hepatic disease

CONTRAINDICATIONS

1. Hypersensitivity to dinoprostone [see WARNINGS and ADVERSE REACTIONS]
2. Acute pelvic inflammatory disease
3. Patients with active cardiac, pulmonary, renal, or hepatic disease

WARNINGS

Dinoprostone, as with other potent oxytocic agents, should be used only with strict adherence to recommended dosages. Dinoprostone should be used by medically trained personnel in a hospital which can provide immediate intensive care and acute surgical facilities.

Dinoprostone does not appear to directly affect the fetoplacental unit. Therefore, the possibility does exist that the previable fetus aborted by dinoprostone could exhibit transient life signs. Dinoprostone is not indicated if the fetus in utero has reached the stage of viability. Dinoprostone should not be considered a feticidal agent.

Evidence from animal studies has suggested that certain prostaglandins may have some teratogenic potential. Therefore, any failed pregnancy termination with dinoprostone should be completed by some other means.

PROSTIN E2 Vaginal Suppository should not be used for extemporaneous preparation of any other dosage form.

Neither the PROSTIN E2 Vaginal Suppository, as dispensed nor any extemporaneous formulation made from the PROSTIN E2 Vaginal Suppository should be used for cervical ripening or other indication in the patient with term pregnancy.

There have been post-marketing reports of serious and life-threatening hypersensitivity reactions including anaphylaxis and angioedema with PROSTIN E2 Vaginal Suppository (dinoprostone). Onset of these reported reactions occurred within minutes to hours after initiation with PROSTIN E2 Vaginal Suppository (dinoprostone). If a hypersensitivity reaction is suspected, if possible remove PROSTIN E2 Vaginal Suppository (dinoprostone), assess for other potential causes of the event, and institute symptomatic and supportive therapy, as needed.

PRECAUTIONS

1. General precautions

Animal studies lasting several weeks at high doses have shown that prostaglandins of the E and F series can induce proliferation of bone. Such effects have also been noted in newborn infants who have received prostaglandin E1 during prolonged treatment. There is no evidence that short term administration of PROSTIN E2 Vaginal Suppository can cause similar bone effects.

As in spontaneous abortion, where the process is sometimes incomplete, abortion induced by PROSTIN E2 may sometimes be incomplete. In such cases, other measures should be taken to assure complete abortion.
In patients with a history of asthma, hypo-or hypertension, cardiovascular disease, renal disease, hepatic disease, anemia, jaundice, diabetes or history of epilepsy, dinoprostone should be used with caution. Dinoprostone administered by the vaginal route should be used with caution in the presence of cervicitis, infected endocervical lesions, or acute vaginitis.

As with any oxytocic agent, dinoprostone should be used with caution in patients with compromised (scarred) uteri.

Dinoprostone vaginal therapy is associated with transient pyrexia that may be due to its effect on hypothalamic thermoregulation. In the patients studied, temperature elevations in excess of 2°F (1.1°C) were observed in approximately one-half of the patients on the recommended dosage regimen. In all cases, temperature returned to normal on discontinuation of therapy. Differentiation of post-abortion endometritis from drug-induced temperature elevations is difficult, but with increasing clinical exposure and experience with PGE2 vaginal therapy the distinctions become more obviously apparent and are summarized below:

<table>
<thead>
<tr>
<th>Endometritis pyrexia</th>
<th>PGE2 induced pyrexia</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>a. Time of onset:</strong> Typically, on third post-abortion day (38°C or higher).</td>
<td>Within 15–45 minutes of suppository administration.</td>
</tr>
<tr>
<td><strong>b. Duration:</strong> Untreated pyrexia and infection continue and may give rise to other infective pelvic pathology.</td>
<td>Elevations revert to pretreatment levels within 2–6 hours after discontinuation of therapy or removal of suppository from vagina without any other treatment.</td>
</tr>
<tr>
<td><strong>c. Retention:</strong> Products of conception are often retained in the cervical os or uterine cavity.</td>
<td>Elevation occurs irrespective of any retained tissue.</td>
</tr>
<tr>
<td><strong>d. Histology:</strong> Endometrium shows evidence of inflammatory lymphocytic infiltration with areas of necrotic hemorrhagic tissue.</td>
<td>Although the endometrial stroma may be edematous and vascular, there is relative absence of inflammatory reaction.</td>
</tr>
<tr>
<td><strong>e. The uterus:</strong> Often remains boggy and soft with tenderness over the fundus, and pain on moving the cervix, on bimanual examination.</td>
<td>Normal uterine involution not tender.</td>
</tr>
<tr>
<td><strong>f. Discharge:</strong> Often associated foul-smelling lochia and leukorrhea.</td>
<td>Lochia normal.</td>
</tr>
<tr>
<td><strong>g. Cervical culture</strong></td>
<td></td>
</tr>
<tr>
<td>The culture of pathological organisms from the cervix or uterine cavity after abortion does not, of itself, warrant the diagnosis of septic abortion in the absence of clinical evidence of sepsis. It is not uncommon to culture pathogens from cases of recent abortion not clinically infected. Persistent positive culture with clear clinical signs of infection are significant in the differential diagnosis.</td>
<td></td>
</tr>
</tbody>
</table>
In the absence of clinical or bacteriological evidence of intrauterine infection, supportive therapy for drug induced fevers includes the forcing of fluids. As all PGE2-induced fevers have been found to be transient or self-limiting, it is doubtful if any simple empirical measures for temperature reduction are indicated.

2. Laboratory tests
When a pregnancy diagnosed as missed abortion is electively interrupted with intravaginal administration of dinoprostone, confirmation of intrauterine fetal death should be obtained in respect to a negative pregnancy test for chorionic gonadotropic activity (U.C.G. test or equivalent). When a pregnancy with late fetal intrauterine death is interrupted with intravaginal administration of dinoprostone, confirmation of intrauterine fetal death should be obtained prior to treatment.

3. Drug interactions
PROSTIN E2 may augment the activity of other oxytocic drugs. Concomitant use with other oxytocic agents is not recommended.

4. Carcinogenesis, mutagenesis, impairment of fertility
Carcinogenic bioassay studies have not been conducted in animals with PROSTIN E2 due to the limited indications for use and short duration of administration. No evidence of mutagenicity was observed in the Micronucleus Test or Ames Assay.

5. Pregnancy
Teratogenic Effects
Animal studies do not indicate that PROSTIN E2 is teratogenic, however, it has been shown to be embryotoxic in rats and rabbits and any dose which produces increased uterine tone could put the embryo or fetus at risk [see WARNINGS].

6. Pediatric use
Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS
The most frequent adverse reactions observed with the use of dinoprostone for abortion are related to its contractile effect on smooth muscle.

In the patients studied, approximately two-thirds experienced vomiting, one-half temperature elevations, two-fifths diarrhea, one-third some nausea, one-tenth headache, and one-tenth shivering and chills.

In addition, approximately one-tenth of the patients studied exhibited transient diastolic blood pressure decreases of greater than 20 mmHg.

Two cases of myocardial infarction following the use of dinoprostone have been reported in patients with a history of cardiovascular disease.

It is not known whether these events were related to the administration of dinoprostone.

Adverse effects in decreasing order of their frequency, observed with the use of dinoprostone, not all...
of which are clearly drug related include:

- Vomiting
- Diarrhea
- Nausea
- Fever
- Headache
- Chills or shivering
- Backache
- Joint inflammation or pain new or exacerbated
- Flushing or hot flashes
- Dizziness
- Arthralgia
- Vaginal pain
- Chest pain
- Dyspnea
- Endometritis
- Syncope or fainting sensation
- Vaginitis or vulvitis
- Weakness
- Muscular cramp or pain
- Tightness in chest
- Nocturnal leg cramps
- Uterine rupture
- Breast tenderness
- Blurred vision
- Coughing
- Rash
- Myalgia
- Stiff neck
- Dehydration
- Tremor
- Paresthesia
- Hearing impairment
- Urine retention
- Pharyngitis
- Laryngitis
- Diaphoresis
- Eye pain
- Wheezing
- Cardiac arrhythmia
- Skin discoloration
- Vaginismus
- Tension

**Post-marketing surveillance**

*Immune system disorders:* Hypersensitivity reactions (e.g., Anaphylactic reaction, Anaphylactic shock, Anaphylactoid reaction).

**DOSAGE AND ADMINISTRATION**

**STORE IN A FREEZER NOT ABOVE –20°C (–4°F) BUT BRING TO ROOM TEMPERATURE JUST PRIOR TO USE.**

**REMOVE FOIL BEFORE USE.**

A suppository containing 20 mg of dinoprostone should be inserted high into the vagina. The patient should remain in the supine position for ten minutes following insertion. Additional intravaginal administration of each subsequent suppository should be at 3- to 5-hour intervals until abortion occurs. Within the above recommended intervals administration time should be determined by abortifacient progress, uterine contractility response, and by patient tolerance. Continuous administration of the drug for more than 2 days is not recommended.

**HOW SUPPLIED**

PROSTIN E2 Vaginal Suppositories are available in foil strips of 5 individually sealed suppositories, NDC 0009-0827-03. Each suppository contains 20 mg of dinoprostone in a mixture of glycerides of fatty acids.

**STORE IN A FREEZER NOT ABOVE –20°C (–4°F).**

This product's labeling may have been updated. For current full prescribing information, please visit www.pfizer.com

Rx only
PRINCIPAL DISPLAY PANEL - 20 mg Suppository Blister Pack

Prostin E2® 20 mg
dinoprostone vaginal suppository
Pharmacia & Upjohn Co., Division of Pfizer Inc, NY, NY 10017
LOT
EXP
PRINCIPAL DISPLAY PANEL - 20 mg Suppository Blister Pack Carton

NDC 0009-0827-03
5—20 mg Suppositories
Rx only
Prostin E2®
dinoprostone vaginal
suppository
20 mg
Pfizer Injectables
# PROSTIN E2

dinoprostone suppository

## Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Item Code (Source)</th>
<th>NDC:0009-0827</th>
</tr>
</thead>
<tbody>
<tr>
<td>Route of Administration</td>
<td></td>
<td>VAGINAL</td>
</tr>
</tbody>
</table>

## Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>DINOPROSTONE (UNII: K7Q1JQR04M) (DINOPROSTONE - UNII:K7Q1JQR04M)</td>
<td>DINOPROSTONE</td>
<td>20 mg</td>
</tr>
</tbody>
</table>

## Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:0009-0827-03</td>
<td>5 in 1 CARTON</td>
<td>01/18/1978</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>1 in 1 BLISTER PACK; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA</td>
<td>NDA017810</td>
<td>01/18/1978</td>
<td></td>
</tr>
</tbody>
</table>

## Labeler

- Pharmacia and Upjohn Company LLC (618054084)

## Establishment

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmacia and Upjohn Company LLC</td>
<td></td>
<td>618054084</td>
<td>MANUFACTURE(0009-0827)</td>
</tr>
</tbody>
</table>

Revised: 10/2018